Quarterly ResultMay 7, 2026, 04:42 PM
Puma Biotech Raises FY26 Revenue Guidance to $222-229M; Q1 Net Loss $3.8M
AI Summary
Puma Biotechnology reported a Q1 2026 net loss of $3.8 million on total revenue of $44.8 million, compared to net income of $3.0 million and revenue of $46.0 million in Q1 2025. Despite the Q1 loss, the company raised its full-year 2026 revenue guidance to $222-$229 million and net income guidance to $16-$19 million, citing increased demand for NERLYNX. Puma also significantly reduced its debt, with outstanding debt reaching zero in early May 2026, and reported positive interim data from its ALISCA™-Breast1 and ALISCA™-Lung1 clinical trials.
Key Highlights
- Raised full-year 2026 total revenue guidance to $222-$229 million, up from $214-$221 million.
- Raised full-year 2026 net income guidance to $16-$19 million, up from $10-$13 million.
- Reported Q1 2026 total revenue of $44.8 million, down from $46.0 million in Q1 2025.
- Recorded a Q1 2026 GAAP net loss of $3.8 million ($0.07 per share), compared to net income of $3.0 million ($0.06 per share) in Q1 2025.
- Generated $15.4 million in net cash from operating activities in Q1 2026, up from $3.6 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $101.5 million as of March 31, 2026.
- Reduced total debt to $11.3 million by March 31, 2026, with final payment made on May 4, 2026, bringing debt to zero.
- Reported positive interim data from ALISCA™-Breast1 and ALISCA™-Lung1 clinical trials for alisertib.